New York, New York — October 7, 2025 — Leads & Copy — OS Therapies Inc. (NYSE American: OSTX) announced its participation in several October 2025 conferences and events. These include the Cell and Gene Meeting on the Mesa in Phoenix, AZ (Oct 6-8), the Roth Annual Healthcare Opportunities Conference in New York City, NY (Oct 9), the FDA/The Osteosarcoma Institute (OSI) Workshop in Washington, DC (Oct 10), BIOFuture 2025 in New York City, NY (Oct 13-15), the 52nd Daytime Emmy Awards in Pasadena, CA (Oct 17), the Maxim Growth Summit: Maxim Group Healthcare Conference in New York City, NY (Oct 22), and BIO-Europe in Vienna, Austria (Nov 3-5).
OS Therapies is a clinical-stage oncology company focused on treatments for Osteosarcoma (OS) and other solid tumors. Their lead asset, OST-HER2, is an immunotherapy targeting the HER2 protein. The company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025.
OS Therapies is also advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC).
Paul Romness, Chairman & CEO
Gerald Commissiong, Chief Business Officer
Nicola J. Mason, BVetMed, PhD, DACVIM, FRCVS, Veterinarian Advisor
Serena Subada, Patient Advocate
Investor Relations: Harrison Seidner, PhD, WaterSeid Partners, OSTX@waterseid.com
Public Relations: Jessica Starman, MBA, Elev8 New Media, media@ostherapies.com
Source: OS Therapies
